GCA
MDGL icon

Greenwood Capital Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Greenwood Capital Associates’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Buy
+682
New +$326K 0.04% 245

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greenwood Capital Associates's MDGL Position: Q1 2026 in Review

Greenwood Capital Associates opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 682 shares worth $357K. The stake represents 0.04% of the portfolio and ranks #245 among its holdings.

378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Greenwood Capital Associates held 682 shares of Madrigal Pharmaceuticals worth $357K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new Greenwood Capital Associates position in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.04% of Greenwood Capital Associates's portfolio in Q1 2026, its #245 holding.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Greenwood Capital Associates's 13F filing for Q1 2026, filed 29 Apr 2026.